ULTRAGENYX PHARMACEUTICAL IN (RARE) Institutional Ownership and Insiders Activity

ULTRAGENYX PHARMACEUTICAL IN (RARE) is widely held by institutional investors, with 295 firms reporting positions valued at approximately $3.35B based on SEC Form 13F filings for the quarter ended June 30, 2026.

Blackrock, Inc. is the largest disclosed holder, reporting approximately $355.75M in RARE holdings in its latest filing.

Recent insider activity includes 3 tracked Form 4 transactions over the last three months, reflecting ongoing executive and director trading activity.